Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 


«12...28293031323334353637383940»
  • ||||||||||  Libtayo (cemiplimab) / Sanofi, Regeneron
    [VIRTUAL] System therapy with cemiplimab of a lymphogenically metastatic collision tumor from Merkel cell carcinoma and squamous cell carcinoma (ePoster Terminal 4) -  Sep 20, 2020 - Abstract #ADO2020ADO_192;    
    In a small collection of cases (n = 26) it could be shown that patients with collision tumors from Merkel cell and squamous cell carcinoma developed metastasis more often (77%) than with solitary Merkel cell carcinoma (40%), showed a poorer therapeutic response and more often died of the disease. We report on the first case of a patient with a lymphogenically metastatic collision tumor from Merkel cell and squamous cell carcinoma under systemic therapy with cemiplimab.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Case series: Immune checkpoint inhibitor therapy in patients with skin tumors and chronic lymphocytic leukemia (ePoster Terminal 1) -  Sep 20, 2020 - Abstract #ADO2020ADO_120;    
    A 71-year-old patient with cSCC parietal, pT3, N0 (i +), M1, L1, Pn1, G3 received therapy with cemiplimab for disseminated cutaneous branches on the head...A 74-year-old female patient with MM of the right calf pT2a, N3c (3/36), M0 developed multiple filiae after 4 doses of adjuvant nivolumab therapy, so that a switch to dabrafenib / trametinib took place...A 74-year-old patient received ipilimumab and nivolumab for treatment of an R1 resected rectal MM...After treatment with prednisolone, therapy with pembrolizumab could be continued...Unexpected side effects or an influence on the CLL did not occur. The increased incidence of hemolytic anemia is an interesting observation that should be investigated in larger studies.
  • ||||||||||  Libtayo (cemiplimab) / Sanofi, Regeneron
    [VIRTUAL] Impressive and rapid therapeutic response for metastatic adnexal carcinoma with cemiplimab (Stream 3) -  Sep 20, 2020 - Abstract #ADO2020ADO_67;    
    In the present case, according to molecular pathological results, anti ‐ PD1 therapy with cemiplimab was carried out analogous to the therapy for metastatic cutaneous squamous cell carcinoma, which led to a rapid and complete tumor response. Anti ‐ PD1 therapy should therefore be considered as an important treatment option for metastatic adnexal carcinoma.
  • ||||||||||  fluorouracil / Generic mfg.
    Journal:  Emerging noninvasive treatments of nonmelanoma skin cancers. (Pubmed Central) -  Sep 13, 2020   
    Each treatment has its own specific indications and side effects, thus there is always room for novel therapeutic approaches. We review new and potential treatments for NMSCs since 2018 including topical sonidegib, cemiplimab, taladegib, posaconazole, radiation therapy (RT), combination RT with vismodegib, PDT, and laser therapies.
  • ||||||||||  Libtayo (cemiplimab) / Sanofi, Regeneron
    Journal, PD(L)-1 Biomarker, IO Biomarker:  Immunotherapy and other systemic therapies for cutaneous SCC. (Pubmed Central) -  Sep 10, 2020   
    Checkpoint inhibition immunotherapy with PD-1 antibodies like cemiplimab have demonstrated response rates of the order of 40% and durability is encouraging: response duration was over a year in 75% of responders in the initial trial. We review the latest data with current immunotherapy drugs and consider the future directions such therapy may take us as well as the role of these therapies in special populations.
  • ||||||||||  tacrolimus / Generic mfg.
    [VIRTUAL] The dilemma of immunotherapy for advanced squamous cell carcinoma in organ transplant recipients: a case report () -  Sep 9, 2020 - Abstract #BAD2020BAD_300;    
    Cemiplimab, an anti‐programmed cell death 1 (PD‐1) immunotherapy, is the only National Institute for Health and Care Excellence‐approved treatment for advanced cutaneous squamous cell carcinoma (CSCC), but it is contraindicated in organ transplant recipients (OTRs) owing to the significant risk of allograft rejection...Maintenance immunosuppression with mycophenolate mofetil, tacrolimus and prednisolone was reduced in 2012 when a well‐differentiated CSCC on his right temple was fully excised...Although immunotherapy has led to advances in the management of advanced CSCC in recent years, immunosuppressed patients have been excluded from all clinical trials, and immunotherapy in these high‐risk individuals is limited to a handful of case reports. This is an area of increasing clinical need, and urgent clinical trials are required to address these issues in this high‐risk population.
  • ||||||||||  Libtayo (cemiplimab) / Sanofi, Regeneron
    [VIRTUAL] Localized iatrogenic lichen nitidus following anti‐programmed cell death 1 antibody treatment () -  Sep 9, 2020 - Abstract #BAD2020BAD_34;    
    A 65‐year‐old man presented to the dermatology on‐call service with a flexural rash on the forearms over a 5‐month period after being recruited for a clinical trial for cemiplimab [anti‐programmed cell death 1 (PD‐1) immunotherapy]...Although the pathophysiology of lichen nitidus is not fully understood, our case supports the hypothesis of lichen nitidus being driven by a T‐cell immunological process relating to the PD‐1 pathway. To our knowledge, this is the first reported case of localized iatrogenic lichen nitidus after anti‐PD‐1 immunotherapy.
  • ||||||||||  Libtayo (cemiplimab) / Sanofi, Regeneron
    Review, Journal:  Cutaneous squamous cell carcinoma (Pubmed Central) -  Aug 18, 2020   
    The immune checkpoint inhibitor cemiplimab is approved for the treatment of inoperable or metastasized cSCC...Since the evidence is low in these cases, a systemic therapy should be used preferentially within clinical studies. Follow-up care should be risk-adapted and includes a dermatological control, supplemented by ultrasound examinations in high-risk patients.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Trial completion date, Trial primary completion date:  Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma (clinicaltrials.gov) -  Aug 10, 2020   
    P1,  N=36, Recruiting, 
    Follow-up care should be risk-adapted and includes a dermatological control, supplemented by ultrasound examinations in high-risk patients. Trial completion date: Aug 2020 --> Feb 2022 | Trial primary completion date: Aug 2020 --> Feb 2022
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal, Monotherapy, PD(L)-1 Biomarker, IO Biomarker:  Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. (Pubmed Central) -  Aug 1, 2020   
    The efficacies associated with PD-1/PD-L1 monotherapy vary significantly across cancer types and PD-L1 expression. This comprehensive summary of clinical benefit from immunotherapy in cancer patients provides an important guide for clinicians.
  • ||||||||||  Libtayo (cemiplimab) / Sanofi, Regeneron
    Review, Journal:  Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma. (Pubmed Central) -  Jul 29, 2020   
    Remarkably, the US Food and Drug Administration (FDA) approved an anti-PD-1 antibody treatment (cemiplimab) for the treatment of patients who are not candidates for curative surgery or curative radiation. It will be a promising treatment option for these types of rare conditions.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Enrollment open:  CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) -  Jul 20, 2020   
    P1,  N=12, Recruiting, 
    Funding: Has not received any funding. Not yet recruiting --> Recruiting
  • ||||||||||  fluorouracil / Generic mfg.
    Journal:  Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. (Pubmed Central) -  Jul 3, 2020   
    Cemiplimab showed antitumour activity and an acceptable safety profile in patients with locally advanced cutaneous squamous cell carcinoma for whom there was no widely accepted standard of care. There are many options for the treatment of AK and cSCC that must be considered in the interdisciplinary care of these entities.